Telomir Pharmaceuticals (NASDAQ: TELO) has announced the peer-reviewed publication of preclinical data in Biomedicine & Pharmacotherapy showing that its lead candidate, Telomir-Zn, restored insulin sensitivity and improved glucose homeostasis in a diet-induced zebrafish model of Type 2 diabetes. The study demonstrated dose-dependent reductions in fasting blood glucose and insulin levels, improved glucose tolerance, and significantly lowered HOMA-IR scores, a widely used measure of insulin resistance.
According to the company, the findings add to a growing body of evidence supporting Telomir-Zn’s mechanism of action through modulation of intracellular metal homeostasis. The biological pathways targeted by Telomir-Zn have been implicated in both metabolic disease and cancer. These results complement the company’s recently FDA-cleared Phase 1/2 clinical program evaluating the drug in patients with advanced or metastatic triple-negative breast cancer.
Telomir Pharmaceuticals is a preclinical-stage biotechnology company developing small-molecule therapeutics designed to target fundamental epigenetic and metabolic mechanisms implicated in cancer, aging, and degenerative disease. The company’s lead program, Telomir-1 (Telomir-Zn), has demonstrated activity in preclinical studies involving modulation of intracellular metal homeostasis, redox balance, epigenetically regulated gene expression, mitochondrial function, and genomic stability.
The implications of these findings are significant for the millions of people affected by Type 2 diabetes, a condition characterized by insulin resistance and impaired glucose metabolism. If Telomir-Zn proves effective in human trials, it could offer a novel therapeutic approach targeting the underlying mechanisms of the disease rather than just managing symptoms. The data also highlight the potential of Telomir-Zn in addressing metabolic dysfunction, which is a key component of many chronic diseases.
For the biotechnology industry, this publication reinforces the scientific rationale behind targeting metal homeostasis and epigenetic regulation as a strategy for treating metabolic disorders. It also demonstrates the translational potential of zebrafish models in preclinical research, which can accelerate the development of new therapies. The company’s ongoing clinical program in triple-negative breast cancer further underscores the broad therapeutic potential of Telomir-Zn.
Investors and stakeholders can access the full press release and additional updates on Telomir Pharmaceuticals through the company’s newsroom at https://ibn.fm/TELO.
